About the Authors
- Yalai Bai
-
Affiliation Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America
- Huan Cheng
-
Affiliation Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America
- Jennifer Bordeaux
-
Affiliation Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America
- Veronique Neumeister
-
Affiliation Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America
- Sudha Kumar
-
Affiliation Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America
- David L. Rimm
-
Affiliation Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America
- David F. Stern
-
* E-mail: DF.Stern@yale.edu
Affiliation Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America
Competing Interests
Dr Rimm is a consultant for Genoptix/Novartis, the exclusive licensee to the Yale owned AQUA technology. Dr. Stern is a partial owner of Phosphoproteomics LLC, which holds intellectual property in phosphorylation-based diagnostics, and he receives royalties for sales of antibody PN2A. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: YB DLR DFS. Performed the experiments: YB JB VN. Analyzed the data: YB HC SK VN. Wrote the paper: YB DLR DFS.